neotiv GmbH
- Industry
- Medical Equipment Manufacturing
- Founded Year
- 2017
- Headquarters
- Magdeburg, Germany
- Employee Count
- 43
Key People
- Chris Rehse - Co-Founder & Chief Executive Officer
- Jana Schumann - Chief Technology Officer
- David Berron - Co-Founder & Chief Scientific Officer
- Julian Haupenthal - Co-Founder & Chief Product Officer
- Emrah Dzel - Co-Founder
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The founding team comprises individuals with over a decade of experience in their respective fields, including neuroscience and product development.
The leadership team's background in neuroscience and product development positions neotiv well to develop and commercialize their digital health solutions effectively.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a significant unmet need for early detection and monitoring tools for Alzheimer's disease and mild cognitive impairment.
With an aging global population, the prevalence of Alzheimer's disease is increasing, underscoring the demand for early diagnostic tools like neotivCare.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for digital cognitive assessment tools is moderately competitive, with several players offering similar solutions.
While there are multiple digital tools for cognitive assessment, neotiv's focus on scientific rigor and integration with healthcare systems may provide a competitive edge.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing reliable and user-friendly cognitive assessment tools involves moderate technical complexity.
Balancing scientific accuracy with user-friendly design is essential for widespread adoption of neotiv's solutions.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents to protect its intellectual property.
Patents can enhance the company's valuation and deter competitors from replicating their technology.
- Financing
-
Aspect: Well-funded
Summary: Neotiv has secured significant funding from reputable investors, totaling over 10 million.
The substantial funding allows neotiv to invest in research, development, and scaling operations to meet market demand.
- Regulatory
-
Aspect: 510k/PMA
Summary: NeotivCare is a CE-marked medical device, indicating compliance with European regulatory standards.
Achieving CE marking demonstrates that neotivCare meets essential health and safety requirements, which is critical for adoption in clinical settings.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.7
- Segment CAGR
- 10.7%
- Market Segment
- Digital Health
- Market Sub Segment
- Cognitive Assessment Tools
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Neotiv is well-positioned to address the growing need for early Alzheimer's detection through its scientifically validated digital health solutions, supported by strong funding and a capable team.